FDA rejects schizophrenia drug from Teva

The US health authority has given its thumbs-down for a schizophrenia drug candidate developed by Teva in a collaboration with French biotech firm Medincell.
Danish national Kåre Schultz is chief executive of Teva, which has just received the FDA's thumbs-down for its candidate drug against schizophrenia | Photo: Amir Cohen/Reuters/Ritzau Scanpix
Danish national Kåre Schultz is chief executive of Teva, which has just received the FDA's thumbs-down for its candidate drug against schizophrenia | Photo: Amir Cohen/Reuters/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

A potentially new treatment for schizophrenia has been sent back to the development phase, the pharmaceutical firm behind the drug, Teva, has announced in a press release on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading